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Abstract
This paper explores a total of six research studies and will contain a literature review and
proposal for further study regarding the effectiveness of the ketogenic diet as an adjuvant cancer
therapy. Each study addresses a variety of different factors involved in KD implementation,
ranging from effects on body composition and lipid profiles, to self-proclaimed quality of life, to
tumor expression and progression under a KD regime. Ultimately, each were divided into three
separate categories depending on the aspects of research that were covered. Two studies, by
Hagihara et.al and Jansen and Walach respectively, discuss the potential benefits of KD in cancer
patients, while two additional studies by Sremanokova et.al and Klement et.al address concerns
regarding the implementation of KD in cancer populations. The final category and studies by
Yang et.al and Erickson et.al claim a lack of significance in the use of KD in clinical practice,
and examine why this is the case. The major findings and limitations of each study will be
discussed in detail, alongside theme comparisons between studies. Based on the findings
discussed, the new research question in the proposal for further study will address the anti-tumor
effects of KD on glioblastoma specifically. The study will be a longitudinal mixed method
design and will only involve participants diagnosed with glioblastomas. The data obtained
through conducted interviews and surveys will be analyzed through audio recordings, written
assessment scales, and questionnaires completed by participants. Additional lab work will be
done for the statistical analysis portion and will observe changes in blood ketone levels, TKTL1
expression, and cfDNA blood levels respectively. The final portion will discuss the consensus
between both the literature review and proposal for further study, which is that KD shows
promise as an adjuvant therapy in cancer populations.

3
Acknowledgements
I dedicate this paper to my older cousin who passed from glioblastoma, as well as my
relatives who have suffered from and are at risk for cancer. Their stories have inspired me to
research this topic.

4
Table of Contents
Introduction: The Ketogenic Diet and Cancer Therapy

5

Literature Review

6

Study Findings Show Promise in Primary Care

7

Concerns Regarding KD for Cancer Populations

8

No Statistical Significance

10

Discussion of the Literature

11

Theoretical Framework

12

Proposal for Further Study

13

Study Design

14

Specific Aims

14

Methodology

15

Data Collection

16

Data Analysis

16

Conclusion

17

References

19

Appendix

21

5
Introduction: The Ketogenic Diet and Cancer Therapy
While many leaps and bounds have been made in the study of cancer and its subsequent
treatment, there is still room for growth in the use of adjuvant therapies to increase efficacy and
quality of life in patients. “In recent years, attention was drawn to the fact that diet-associated
factors may be involved in the development and progression of cancer” (Jansen & Walach, 2016,
para. 2). That said, one such avenue that shows promise is the ketogenic diet, a high-fat lowcarbohydrate diet with increased protein consumption. The traditional ketogenic diet consists of
a 4:1 ratio, which “delivers 90% of its calories from fat, 8% from protein and only 2% from
carbohydrate” (National Center for Biotechnology Information, 2020, para. 9). Its practice has
already been utilized as a second-line treatment for epilepsy in pediatric populations with much
success.
However, there is debate in the scientific community regarding whether or not the
implementation of KD is as effective in cancer populations as it is in epileptic populations. Many
speculate that KD may provide an antitumor effect by creating an unfavorable environment for
cancer cells through a decrease in carbohydrate consumption. Such cells thrive on the glucose
contained in carbohydrates, and it is through this diet, alongside the use of standard cancer
therapies such as chemo and radiotherapy, that tumor progression can be halted, increased
tolerability to treatment, and improved quality of life for patients may be achieved. However,
according to the National Center for Biotechnology Information (2020), “to further elucidate the
mechanisms of the ketogenic diet as a therapy and evaluate its application in clinical practice,
more molecular studies as well as uniformly controlled clinical trials are needed” (para. 3). The
following thesis, including a comprehensive review of the research literature and proposal for
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further study, is a way to provide additional insight into this area of interest, and to answer the
question of how effective the ketogenic diet is for adjuvant cancer therapy in clinical practice.
Literature Review
The Dominican University databases were utilized in the search for information
regarding the ketogenic diet and cancer treatment. All search terms were variants of these two
descriptions, and the research was confined to the following databases: Iceberg, CINAHL,
PubMed, and Cochrane. Six studies were used in total, and only ones that involved human trials
and introduced KD as an adjuvant therapy were taken into consideration. Due to the versatility of
KD effects on different cancer types, studies that only reviewed a single form of cancer were
excluded from this review, but measures were taken to ensure that these studies provided
evidence related to their respective cancer markers and how they correlate with KD. All studies
involved were limited to either systematic reviews, randomized controlled trials, or metaanalyses.
Each study was divided into three separate categories. In the first category, the sources
showed promising evidence for KD as a beneficial form of therapy alongside other cancer
treatments. However, despite their many benefits, they also discuss how these results are not
enough to support the practical use of KD in clinical settings. They merely serve as avenues for
further study and provide valid evidence to support the idea that KD should continue to be
researched as an alternative form of cancer therapy. The second category included sources that
addressed the concerns regarding the use of KD on cancer populations and the potential barriers
that need to be considered before it can be clinically implemented. The final source category
described how KD implementation yielded inconclusive evidence and should not be considered
for clinical practice.
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Study Findings Show Promise in Primary Care
Hagihara et.al (2020) came together to conduct a study that evaluated the effectiveness of
a new ketogenic diet regimen in patients with different types of stage IV cancer. The purpose
was to determine whether KD could be used as a supportive therapy in clinical practice and to
establish the extent that carbohydrate restrictions could be implemented in those with cancer.
Fifty-five participants gave their consent in total, with data only being taken from 37 partaking in
KD for three months or more. Major findings of the study yielded that the effects of KD differ
depending on the cancer type, but across their respective lab markers and lipid profiles, KD in
combination with chemotherapy or radiation was correlated with a decrease in tumor and
metastases size. Paired with these standard cancer therapies, Hagihara et.al (2020) stated that
“The present ketogenic diet regimen had better tolerability, with less nausea, fatigue, and
constipation, and it induced stable adherence” (Discussion section, para. 5). In addition, “results
suggest that weight loss is not a toxic effect of the ketogenic diet” (Discussion section, 2020,
para. 5) despite weight loss risk in cancer patients. Many maintained adequate nutrition and
muscle mass despite the change in diet.
These results indicate that adverse symptoms and body composition risks associated with
the implementation of KD in cancer populations are not a primary concern. Overall, KD seems
to have a positive effect on cancer patient’s long-term prognoses and may contribute to longterm survival with controlled use. However, some results may be controversial due to limitations
in dietary restriction. If dietary restriction is insufficient, it may alter patient lab results and leave
anti-tumor effects unclear. In summary, should future modifications and additional research be
pursued, KD offers hope as a promising avenue for support therapy in cancer populations.
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An additional study by Jansen and Walach (2016) wanted to evaluate whether the levels
of TKTL1, a novel marker of tumor cell glycolysis, are affected by a ketogenic diet, and whether
adherence to KD is associated with a better prognosis in patients with cancer. Seventy-two
subjects diagnosed with any form of cancer since January 2001 were included in the study.
According to Jansen and Walach (2016), “Results obtained suggest that there is a positive link
between the expression of TKTL1 and cancer progression, and a negative link between ketogenic
diet and TKTL1 expression” (Discussion section, para. 6). These results indicate that the
expression of TKTL1 is associated with tumor progression. However, when KD was introduced,
TKTL1 expression was observed to be halted. Jansen and Walach (2016) claim that “reduced
expression levels of TKTL1, which are a negative predictor of cancer progression, may reflect
the effect of a ketogenic diet” (Discussion section, para. 6). Noting these changes in lab values,
Jansen and Walach surmounted that it may be beneficial to advise individuals with cancer to
adopt KD due to the altered expression of TKTL1.
However, despite altered TKTL1 values, patients are still at risk for recurrences or
metastases. Additionally, not all individuals maintained a consistent regime while on KD, which
may have skewed overall results.
Concerns Regarding KD for Cancer Populations
While benefits of the ketogenic diet are certainly present in study findings, there is still
skepticism surrounding the safety of its use for individuals with cancer. Klement et.al (2020)
were concerned with the skepticism regarding lack of adequate clinical research supporting the
effectiveness of the ketogenic diet as a cancer therapy. They claim that a “lack of studies
occupying higher levels in typical ‘evidence hierarchies’ has been emphasized by some
authors...discouraging the clinical application of KDs” (Klement, p. 5, 2020). This is known as
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“methodological skepticism” and serves as a strong barrier towards confidence in KD efficacy.
In an effort to address such concerns, the subsequent study was executed and focused on research
that had implemented KD in medical oncological treatments. Despite previous concerns, data
found that there are large beneficial effects of KD on body composition in both overweight and
frail populations, as well as those at risk for excessive weight loss due to cancer or while
undergoing cancer treatment. Additional evidence by Klement et.al (2020) suggests that KD
“acts synergistically with radiotherapy, chemotherapy, and other therapies” (p. 9), as well as
“[deprives] cancer cells of important anti-oxidative substrates'' (p. 9) to inhibit growth. The
evidence supporting KDs as a supportive cancer therapy is steadily growing and suggests several
benefits in clinical practice.
Sremanokova et.al’s (2018) study was concerned with the nutritional aspect of KD and
aimed to determine its effects on cancer patient’s nutritional status, as they stated that “KD has
the potential to influence many physiological processes…[incurring] weight loss, muscle wasting
and severe inflammation, which can lead to morbidity and poorer quality of life” (Introduction
section, para. 4). A total of 102 participants ranging 34 to 87 years old were included in the
study, all with a variety of different cancer types at different stages. Based on analysis of
anthropometry, lipid profiles, tumor effects, and adverse events, the study found that KD does
not cause life-threatening events and may even be feasible as a therapy with the right parameters.
However, Sremanokova et.al (2018) claim that KD “adherence is low and possibly linked to a
limitation in diet delivery, as well as a lack of monitoring and follow-up” (Conclusion section,
para. 1). This indicates that while no life-threatening events were observed, lack of proper KD
implementation may have contributed to these results. Other barriers such as lack of ketone
measurements, which is a staple value in evaluating ketogenic effectiveness, short KD duration,
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and small sample sizes, were also noted, which made it difficult to reach a valid conclusion.
Sremanokova et.al deduced that while there are sound theoretical bases for KD suppressing
tumor growth across different cancer types, strong conclusive evidence in clinical practice is
lacking.
No Statistical Significance
The following studies were some of the few that claimed there was inadequate evidence
to support the beneficial effects of the ketogenic diet on antitumor therapy. In Yang et.al’s
(2021) study, rigorous comparison of different factors such as lipid profiles, tumor markers, level
of satisfaction, and adverse effects found that “most evidence did not have any statistical
significance and therefore the effects of LCKDs as an adjuvant therapy on cancer management
was inconclusive” (Discussion section, para. 5). Yang et.al bring up a very important point in the
study’s discussion portion, claiming that it is difficult to accurately draw comparisons between
studies because each follows its own set of protocols and are within different parameters. Data
collection in one study may include qualitative aspects that give more depth to the patient’s
experience while others may choose to focus on statistical values seen in laboratory results or
profiles. This lack of consistency in data, in the words of Yang et.al (2021), makes it “difficult to
obtain an accurate conclusion to dictate the ketogenic diet as adjuvant therapy for cancer”
(Discussion section, para. 10). As such, it cannot be exclusively proven whether KD is effective
or ineffective as an adjuvant form of cancer therapy.
Erickson et.al (2017) take a similar approach to this claim, and ultimately they come to
the same conclusion as Yang: “...evidence on [ketogenic] benefits regarding tumor development
and progression as well as reduction in side effects of cancer therapy is missing” (p. 11). Similar
to the previous study, their goal was to assess the effectiveness of a KD regime, specifically in
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regards to weight maintenance, and acquire structure to determine how to implement this regime
best in cancer patients. However, after the analysis of results related to tumor progression,
regime duration, quality of life, and body composition, ultimately no statistically significant
evidence could be found. Erickson et.al (2017) claim that “The studies are limited by their
sample sizes and lack in homogeneity of type, location and cancer stage, and thus, results cannot
be compared” (Results section, p. 2, 2017). In addition to this, “studies in the area of cancer lack
consistency and do not utilize clearly comparable and consistent standardized dietary protocols”
(Results section, p. 2, 2017). Validity and reliability of results are unable to be achieved in the
case of inconsistent study implementation. For this reason, interpretation of the data presented
for KD effectiveness in cancer therapy cannot be regarded as accurate. As a result, Erickson et.al
(2017) suggest that “More robust and consistent clinical evidence investigating comparable
patient groups with comparable methodology, dietary protocols and consistent results are
warranted before the KD can be recommended for any single cancer diagnosis or as an adjunct
therapy” (Conclusion section, p.1)
Discussion of the Literature
While there have certainly been benefits observed in the use of the ketogenic diet
alongside cancer therapy, such as slowed tumor progression and maintenance of healthy body
composition, concrete and measurable evidence of said benefits are still largely inconclusive.
Many of these studies had limitations in their research that were not addressed or could not be
overcome. A common theme in such limitations mainly had to do with small sample sizes, lack
of homogeneity between cancer types, inconsistent diet implementation, and unequal study
parameters. Smaller sample sizes indicate an inaccurate representation of the larger cancer
population, and with each study conducting their research with different sets of parameters,
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results indicate an unreliable portrayal of the effects of KD as an adjuvant cancer therapy. In
addition, the purpose of including a variety of different cancers was to determine how KD affects
each one individually. However, the broader the range of conditions to identify and research, the
more difficult it becomes to accurately compare data. This lack of reliability and validity
between studies creates a skewed cesspool of results, and despite the benefits observed, they are
not enough to place sure confidence in clinical practice.
However, this does not mean that KDs lack promise in the potential to strengthen cancer
therapy. If there is one thing that the studies share in common, it is the need for further research
into this avenue of treatment, as many of them have claimed themselves. More controlled trials
are necessary before KD can seriously be considered as an adjuvant therapy, and with new
research being presented every year, the hope is that these future studies will address concerns
that their predecessors have identified before them. Overall, while the research into KD is still in
its infant stages among the cancer population, the aforementioned studies recognize that it is a
valid adjuvant therapy to be pursued further, so long as limitations are addressed and attempted
to be corrected.
Theoretical Framework
As briefly mentioned, a common theme across the studies was the participants’ inability
to utilize the ketogenic diet to completion. Many stopped KD a quarter or midway through, and
others, despite using KD to completion, were not consistent with their diet’s implementation.
While this may have skewed data and results, it is important to understand that, especially in the
case of cancer treatment, the patient always has the final say when it comes to decisions of care.
According to Orem’s Self-Care Deficit Nursing Theory, “People are distinct individuals” and
“should be self-reliant, and responsible for their care, as well as others in their family who need
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care” (Nursing Theory, n.d., p. 3). If there are deficits in a person’s ability to administer selfcare, that is when nursing intervention must be implemented. This creates an interpersonal
relationship between nurse and patient, where the nurse communicates accurate and reliable
information regarding a patient’s condition and treatments, and the patient is enabled to make
well-educated decisions about administration of self-care.
In the case of cancer populations, medical and therapeutic interventions will likely be
implemented to better manage their conditions, no matter the cancer type. That being said, the
patient will always be the final decision maker when it comes to actual implementation of these
interventions. The nurse is responsible for “acting for and doing for others; guiding others;
supporting another; providing an environment promoting personal development in relation to
meet future demands; and teaching another” (Nursing Theory, p. 5). For ketogenic diet
implementation, the role of the nurse is to provide an appropriate avenue for participants to be
informed, and in doing so, encourage confidence in their care regardless of whether or not they
choose to participate in the diet change. It is crucial that KD research considers this aspect of
nursing, as it plays an important role in how data will be collected and to what extent it will be
accurate.
Proposal for Further Study
Due to the limitations that have been identified by ketogenic diet research, specifically in
relation to cancer populations, more controlled measures will need to be taken for further study
in this area of interest. Small sample sizes were a common barrier seen among the studies. In
particular, participant's inability to continue KD to completion led to attrition, leading to
inconclusive results. Additionally, insufficient data collection was largely due to the
incomparability of different cancer types, all of which were studied at different stages and with
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different biomarkers. With such large inconsistencies in research, it is essential to implement a
more concise method of study to analyze the specific effects of KD on cancer populations. For
more accuracy and consistency across data, the subsequent study will address the following
research question: What are the effects of a ketogenic diet on tumor progression in those with
glioblastoma?
While changes will be implemented in the study’s protocols to address these concerns, it
will still be difficult to fully control all extraneous variables. Participants have a right to
informed consent, and we cannot blind them to the study’s implementation methods without
proper education of the risk-benefit analysis of KD. Margins of error related to how involved
participants will be will also need to be considered. From an ethical standpoint, we cannot force
a patient to undergo any form of treatment no matter the benefits, and in the case of KD, the
participant has the final say in whether or not they want to complete the trial. With this in mind,
the following parameters were designed to carry this research study forward.
Study Design
A longitudinal mixed method design will be implemented for this study. Collection of
data to determine the effects of the ketogenic diet in patients diagnosed with glioblastoma will
need to take place over a longer period of time. Both qualitative and quantitative data will be
collected for analysis of holistic effects of KD on cancer patients.
Specific Aims
The primary objective of collecting quantitative data will be to precisely measure changes
in lab values specific to glioblastoma tumor progression during a ketogenic diet and achievement
of ketogenesis over a six-month period. The secondary objective will be to assess participants’
perception of pain and changes in symptoms related to ketogenic diet implementation not

15
associated with other forms of cancer treatment. Qualitative data will additionally be collected to
explore participant feelings before and after adoption of a ketogenic diet
Methodology
A total of ninety participants will be included for KD implementation, and due to the
conflicting data of different cancer types, this study will only consist of those with glioblastomas.
Advertising will be administered both physically through paper flyers posted at the UCSF Brain
Tumor Center in San Francisco and electronically on the News and Blog section of the National
Brain Tumor Society website. Both advertising campaigns will signify that trial screening is
open for a two-month window. To meet criteria for the design, participants must be over the age
of eighteen and have been diagnosed with glioblastoma for at least two weeks. As mentioned
previously, we cannot force participants to undergo KD for any length of time they do not wish
to. To decrease the likelihood of this occurrence, an educational session will be held during the
screening process to inform the participants of the parameters this study will implement. The
session will include education on what KD is, what specific KD type will be implemented and
for how long, the potential effects it may have on tumor progression, and the lab work and data
collection that will be done throughout the study to observe the effects of KD.
Selection of participants will be conducted as a rolling admission, meaning that all
applications from participants will be evaluated as they are received rather than altogether once a
deadline is reached. Participants will be given a three-week period after the study’s educational
session to decide whether they want to be involved in the study. Should they choose to
participate, they will partake in a thirty minute interview session before KD implementation to
discuss feelings regarding their current treatment and what they are hoping to achieve through
implementation of KD. Another thirty minute interview session will take place at the end of the
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study asking the same questions now having received KD and whether or not their expectations
were met, and to what extent. Each interview session will be recorded and analyzed at the
study’s conclusion to determine significance of KD implementation.
Data Collection
The ketogenic diet will be administered over a six month period, and among that time
four blood tests will additionally be given. The lab work will be to obtain biomarkers related to
KD effects, with ketogenesis being observed through ketone levels in the blood and glioblastoma
tumor progression being observed through TKTL1 expression and cfDNA levels in the blood
respectively. The tests will take place before the KD diet is implemented to obtain participant
baselines, again two months into the study, then four months in, and finally at the study’s
conclusion. Additionally, at the two month and four month intervals, a survey will be given to
determine current feelings on KD’s implementation, symptom assessment using the short form
of the Brief Pain Inventory (BPI) assessment tool, changes in health and/or quality of life, and
how confident they feel that they will continue KD to completion. Overall, the total length of
enrollment, diet implementation, and data collection will take place over the span of two years.
Data Analysis
For analysis of quantitative data, descriptive statistics will be used to describe
demographic characteristics along with multiple regression, which will examine differences in
lab values over time. Analysis will additionally be correlation based to determine the relationship
between KD diet implementation and tumor progression, as measured by the Pearson r
correlation technique. For analysis of qualitative data, content analysis will be used and
measured by Colaizzi’s method of data analysis, as described below in Fain’s (2021) sixth
edition Nursing Research text:
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1. Describe lived experience under study.
2. Collect participant descriptions of the lived experience.
3. Read all participant’s descriptions of the lived experience.
4. Extract significant statements.
5. Articulate the meaning of each significant statement.
6. Aggregate the meanings into clusters of themes.
7. Write an exhaustive description.
8. Return to participants for validation of the exhaustive description.
9. Incorporate any new data revealed during validations into final exhaustive description.
Conclusion
While there have been a variety of different research designs and scrutiny regarding the
ketogenic diet as a cancer therapy, the consensus among the scientific community is this: the
ketogenic diet, while still in its infancy as a therapeutic cancer intervention, shows promise in its
effectiveness and potential for long-term benefit. Its influence on tumor progression seems
notable when paired with additional intervention such as chemo or radiotherapy, and this effect
extends across a wide variety of cancer types. However, these benefits can only be considered
with partial strength due to the extensive limitations the study designs faced. Most sample sizes
were too small to accurately represent KD effects on all cancer populations. Additionally, each
type of cancer used different methods of measurement that were incomparable with each other.
Each study also had their own set of parameters that could not be replicated or were not properly
explained. This lack of homogeneity between cancer types, implementation, and observation
makes it difficult to reach a joint conclusion.
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As it stands, KD cannot be properly implemented into clinical practice without further
research and study analysis. While it has clearly shown promising results in the avenue of
adjuvant cancer therapy, there are still too many uncertainties that may put patients at risk if
implemented with the current knowledge we have. That being said, the ideas that KD has
introduced serve as an exciting opportunity for cancer populations in the pursuit of alternative
therapy, all with the goal of improving quality of life. More controlled trials will need to be
conducted to ensure that results are obtained within similar design frameworks, which will build
validity and reliability that can pave the way for future studies. For nurses and patients alike,
knowing the effects on different cancers is certainly beneficial, but in the best interest of
consistent research and data collection, studies should strive for homogeneity in cancer types to
allow for more authentic variety in KD effects. Tumor progression, body composition, and
adverse symptoms seem to be the avenues that are most promising for KD implementation.
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Appendix A
Authors/Citation

Purpose/Objective of
Study

Sample- Population
of Interest, Sample
Size

Study Design

Major Findings(s)

Yang, Y.-F.,
Mattamel, P. B.,
Joseph, T., Huang, J.,
Chen, Q., Akinwunmi,
B. O., Zhang, C. J. P.,
& Ming, W.-K.

Investigate the
efficacy of the low
carb keto diet as an
adjuvant therapy in
antitumor treatment
compared to non-keto
diets

216 subjects who
underwent the keto
diet to completion (4–
24-week range)

Systematic review and
meta-analysis

Results show
inadequate evidence to
support beneficial
effects of LCKD on
antitumor therapy. Not
enough studies on the
mechanism of the keto
diet, need more

Establish the role of
the low carb keto diet
in cancer treatment
more clearly

Need more practical
guidance on use in
cancer patients such as
timing of the
intervention, patient
age, the severity of the
disease, and
nutritional status.
These factors may
affect the efficacy of
KD, but many
previous studies have
not addressed this.

Include a bigger
population to precisely
compare the KD group
and the non-KD
group: same or similar
types of cancers
affecting the same

Strengths

All studies involved
human subjects

Excluded trials that
were non-randomized,
had no comparison
group, were nonhuman species, were
conference abstracts,
book chapters,
reviews, or other
forms without detailed
empirical data and
have no exposure or
outcome of interest

Included extensive
coverage of lipid
profiles to analyze the
range of effect of the
ketogenic diet across
multiple factions

Limitations

All the papers were
mostly heterogeneous,
leading to inaccurate
comparison between
results and studies

All the included
papers had different
types of cancers and
treatment, made it
difficult to compare
and provide a
conclusive result
(different cancer
pathogenesis and
pathophysiology may
cause different
responses to LCKDs)
All had small
populations
Difficult to compare
all the papers in the
same sequence
because each
measured a different
type of parameter
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organ, such as the
ovaries, uterus,
prostate, pancreas,
etc., to have a precise
comparison group
Hagihara, K.,
Kajimoto, K., Osaga,
S., Nagai, N.,
Shimosegawa, E.,
Nakata, H., Saito, H.,
Nakano, M.,
Takeuchi, M., Kanki,
H., Kagitani-Shimono,
K., & Kijima, T.

Study the
effectiveness of a new
keto diet regimen in
patient with different
types of stage IV
cancer
Determine the
effectiveness of the
keto diet as a support
therapy and establish
the degree and
duration of carb
restriction more
clearly in those with
cancer

55 gave consent, 37
took the keto diet

Case series study

Patients diagnosed
with cancer by
histology or cytology
and evaluated as stage
IV on computed
tomography (CT),
magnetic resonance
imaging (MRI), or
surgery by their
attending oncologist;
performance status <2;
and could take foods
orally

The effects of the
ketogenic diet alone
differ depending on
the type of cancer, but
the combined effect of
the ketogenic diet with
chemotherapy or
radiation is promising

Evaluated effects of
the ketogenic over a
longer course of time
Addressed concerns
regarding dietary
restrictions in cancer
patients and included
so in their study

Demonstrated that the
ketogenic diet regimen
showed stable
adherence and induced
functional ketosis with
high reproducibility
and was well
controlled in advanced
cancer patients
receiving
chemotherapy.

15M 22F
Age 54.8 ± 12.6

Lack of homogeneity
between cancer types
and treatment, leading
to inaccurate
comparison between
results
Lack of control group
makes it difficult to
draw meaningful
conclusions after
implementation of
independent variable
(keto diet)

Seems to have an
effect on long-term
survival of advanced
cancer patients
Jansen, N., & Walach,
H.

Evaluate whether the
levels of TKTL1 are
associated with tumor
status and progression,
and are affected by a
ketogenic diet, and
whether adherence to
a ketogenic diet is
associated with a
better prognosis in
patients with cancer

78 subjects diagnosed
with any form of
cancer since Jan 2001.
Diagnosed with any
type of tumor, or had
experienced the
recurrence of a tumor
or metastasizing
disease during the 10
years previous to the
initiation of the study

Systematic
prospective cohort
study

Results suggest that it
may be beneficial to
advise tumor patients
to adopt a ketogenic
diet, and that those
who adhere to it may
have positive results
from this type of diet
Keto diet as a
complementary

Present study is the
first to describe the
effects of a ketogenic
diet in patients with
cancer in primary care

No control condition
or control group
matched for important
predictors

Levels of TKTL1
were measured
continuously in the
patients

Difficult to preclude
that the effects
observed are not
confounded
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treatment to tumor
therapy must be
further studied in
rigorously controlled
trials
Negative link between
ketogenic diet and
TKTL1 expression
In summary, the
present study has
demonstrated that a
ketogenic diet is
feasible and likely
beneficial for patients
with cancer in primary
care, who have been
treated for their
primary cancer, since
it altered the
expression of TKTL1,
a novel and potentially
useful marker to
monitor the metabolic
state of the body
regarding aerobic
glycolysis, and to
evaluate the potential
progression of nonend stage tumor
disease
Results should serve
as guidance to
encourage further
research
Sremanakova, J.,
Sowerbutts, A. M., &
Burden, S.

KDs have the
potential to influence
many physiological
processes. It is

102 participants
ranged 34 to 87 years
old. Brain, rectal, or
mixed cancer sites
at an early or

Systematic review

KD is potentially
feasible and does not
cause life-threatening
events in patients with
cancer. However,

Included randomized
and nonrandomized
control trials,
prospective cohort
studies, retrospective

limited information on
eligibility of
participants, and
details of recruitment
were only reported in
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therefore important to
determine whether KD
adversely affects
nutritional status in
individuals with
cancer.
Evaluate the current
evidence on
anthropometry,
metabolic changes and
systemic inflammation
in individuals with
cancer who were
following a KD

advanced disease
stage. Intervention
ranges from 2.4-134.7
weeks (0.5-31
months)

adherence is low and
possibly linked to a
limitation in diet
delivery, as well as a
lack of monitoring and
follow-up
sound theoretical
bases for KDs
suppressing tumor
growth. However,
strong conclusive
evidence in clinical
practice is still lacking

cohort studies,
observational and case
studies

two studies
Unspecified inclusion
criteria, had a short
duration on a KD that
would not result in
any potential benefits
that could be
attributed to ketosis,
some studies didn’t
report or measure
ketones

Studies lacked
precision and
reliability, had a small
sample size,
insufficient statistical
analysis, limitations in
the design,
methodology and
outcomes reported
none of the studies
assessed the quality of
evidence using risk
assessment tools
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Klement, R. J.,
Brehm, N., &
Sweeney, R. A.

Summarize data from
clinical studies that
have tested KDs along
with other treatments
used within medical
oncology to determine
the effectiveness of
KD as a
complementary
treatment

Sample size unknown

Systemic review

Large beneficial
effects of KDs on
body composition for
both overweight
patients who benefit
by losing body weight
and fat mass while
maintaining fat-free
mass and patients at
risk for excessive
weight and lean mass
loss such as head and
neck cancer patients
undergoing radio
chemotherapy or
pancreatic cancer
patients
KDs as a supportive
cancer therapy is
growing and suggests
several beneficial
effects. The largest
evidence so far is for
beneficial effects on
body composition in
both overweight and
frail patient
populations

Analyzed the effects
of a ketogenic diet
across a range of
different cancers

Only two of the
studies had an a priori
published study
protocol
The majority of
studies included in
this review suffered
from different sources
of bias
Small sample sizes
Lack of a control
group, or lack of
randomization giving
rise to self-selection,
allocation, and
performance bias

26

Erickson, N.,
Boscheri, A., Linke,
B., & Huebner, J.

Assess clinical
evidence of isocaloric
keto diet regimes and
determine evidencebased
recommendations for
treating cancer
patients with diet
regime

330 total patients
included, but only 177
followed KD at any
duration of the study
Only 67-177 adhered
to dietary
recommendations of
study

Systematic review

Evidence of benefits
on tumor development
and reduction in side
effects is missing
Need more robust and
consistent clinical
evidence
Need more
comparable
methodology, dietary
protocols, and
consistent results

Only involved
original, peerreviewed articles
Addressed many
concerns regarding
KD use and discussed
lack of evidence in
literature to support

Low adherence to diet
by cancer patients
Inconsistent and
poorly described
protocols
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Appendix B
Sample survey questionnaire regarding participant involvement in the ketogenic diet. Includes a rating scale ranging from 1-5
and brief margins to describe personal feelings more in depthly.
● Have you felt any changes in health since starting KD?
1 - I feel no different 2 - I feel worse 3 - I feel better
If you circled 2 or 3 in the previous question, please explain:
______________________________________________________________
● How difficult has it been maintaining KD regularly?
1 - Not Difficult 2- Slightly Difficult 3 - Neutral 4 - Difficult 5 - Very Difficult
Briefly explain why:
_______________________________________________________________
● Have you experienced symptoms separate from your cancer treatment since starting KD?
YES

NO
If yes, please state them below:
_______________________________________________________________

● How confident do you feel about completing the KD diet?
1 - Not Confident 2- Slightly Confident 3 - Neutral 4 - Confident 5 - Very Confident

